ArticleProbiotics and antimicrobial proteins2026
Gut Microbiota from Patients with Long COVID Persisting for 2 Years Result in Alterations in Mice that Resemble Post-COVID Symptoms.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Human gut microbiota (GM) has been identified as a potentially important factor influencing the development of long COVID (LCOVID). The aim of this study was to understand the GM of LCOVID, which lasted for two years, in order to improve public awareness. Human gut microbiota and its metabolites were assessed in a healthy control group (n = 11) (HC) unexposed to SARS-CoV-2 and an LCOVID group (n = 11) in Hainan, China, using Shotgun metagenomics and liquid chromatography-mass spectrometry (LC-MS) of feces. The causal role of the microbiota in LCOVID was further validated by transplanting feces from the subjects into ABx mice using Histopathology and 16 S rRNA sequencing. Fecal microbial diversity was lower in patients with LCOVID compared with that in HC. Pro-inflammatory bacteria such as Streptococcus_salivarius and Streptococcus_parasanguinis increased, whereas anti-inflammatory bacteria such as Faecalibacterium_SGB15346 and Alistipes_onderdonkii decreased. Fecal metabolites from LCOVID were impaired in carbohydrate degradation, indole production, SCFA production, and fatty acid degradation. Transplantation of feces from patients with LCOVID into mice results in lung inflammation, intestinal inflammation, and anxiety. In addition, transplanted mice showed worse outcomes during Klebsiella_pneumoniae infections. Transplanted mice and the key bacteria Streptococcus_salivarius had the same worse outcomes in the D-IBS model by limb binding. GM from patients with LCOVID was altered significantly and sufficiently to promote LCOVID symptoms in mice, suggesting that it may be a potential therapeutic target.
Indexed as
Identifiers
42667585What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.